📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV. (2023)

First Author: Cargill T

Attributed to: Immunity in the face of diversity and the development of novel potent HCV vaccines funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.jhepr.2023.100885

PubMed Identifier: 37791379

Publication URI: http://europepmc.org/abstract/MED/37791379

Type: Journal Article/Review

Volume: 5

Parent Publication: JHEP reports : innovation in hepatology

Issue: 11

ISSN: 2589-5559